Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
•
General Rheumatology
•
Polymyalgia rheumatica
•
Hospital Medicine
What would be the preferred treatment option for PMR if patient develops gastric perforation soon after initiation of steroids?
Answer from: at Community Practice
Of course Kevzara.
Sign in or Register to read more
23977
Related Questions
How do you approach the management of digital ischemia in a critically ill patient with infection, but no evidence of active rheumatologic disease?
Would you start anticoagulation in a previously heathy patient with a new diagnosis of ANCA vasculitis (+PR3, RPGN, crescents on kidney biopsy) who presented with pancreatitis, splenic and renal infarcts and was also found to have CMV viremia?
How would you approach EGPA with renal involvement that was on maintenance Rituximab, last infusion two months ago and develops new onset liver involvement?
How would you approach management of a patient with a medium-to-large vessel vasculitis who developed perforation of the stomach and colon on steroids and cyclophosphamide?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
When starting stress dose steroids for patient with primary adrenal insufficiency, how do you decide whether to start hydrocortisone 100 mg every 8 hours versus 50 mg every 6 hours?
What would be your approach to managing severe ANCA-associated vasculitis in a patient who is also septic from a bacterial infection?
What biologic or conventional/synthetic DMARD would you use as a steroid sparing agent in a patient with GCA and a history of diverticulitis?
What options are available for patients who require high dose steroids while taking strong CYP4A4 inducers?
What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?